165 related articles for article (PubMed ID: 36725768)
1. Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison.
Huizinga T; Choy E; Praestgaard A; van Hoogstraten H; LaFontaine PR; Guyot P; Aletaha D; Müller-Ladner U; Tanaka Y; Curtis JR; Fleischmann R
Rheumatol Ther; 2023 Jun; 10(3):539-550. PubMed ID: 36725768
[TBL] [Abstract][Full Text] [Related]
2. A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis.
Edwards CJ; Sawant R; Garg V; Du EX; Friedman A; Betts KA
Rheumatol Ther; 2021 Mar; 8(1):167-181. PubMed ID: 33244703
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
4. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
Bergman M; Buch MH; Tanaka Y; Citera G; Bahlas S; Wong E; Song Y; Zueger P; Ali M; Strand V
Rheumatol Ther; 2022 Dec; 9(6):1517-1529. PubMed ID: 36125701
[TBL] [Abstract][Full Text] [Related]
5. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
[TBL] [Abstract][Full Text] [Related]
6. Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs.
Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; van Hoogstraten H; Mangan E; Carita P; Huynh TM
Adv Ther; 2019 Apr; 36(4):817-827. PubMed ID: 30864105
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
[TBL] [Abstract][Full Text] [Related]
8. Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.
Curtis JR; Yun H; Chen L; Ford SS; van Hoogstraten H; Fiore S; Ford K; Praestgaard A; Rehberg M; Choy E
Rheumatol Ther; 2023 Aug; 10(4):1055-1072. PubMed ID: 37349636
[TBL] [Abstract][Full Text] [Related]
9. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis.
Boyce EG; Rogan EL; Vyas D; Prasad N; Mai Y
Ann Pharmacother; 2018 Aug; 52(8):780-791. PubMed ID: 29482351
[TBL] [Abstract][Full Text] [Related]
10. Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis.
Burmester GR; Bykerk VP; Buch MH; Tanaka Y; Kameda H; Praestgaard A; van Hoogstraten H; Fernandez-Nebro A; Huizinga T
Rheumatology (Oxford); 2022 May; 61(6):2596-2602. PubMed ID: 34508594
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials.
Conaghan PG; Pavelka K; Hsieh SC; Bonnington TL; Kent TC; Marchbank K; Edwards CJ
Rheumatol Adv Pract; 2023; 7(1):rkad017. PubMed ID: 36794283
[TBL] [Abstract][Full Text] [Related]
12. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
Fleischmann R; van Adelsberg J; Lin Y; Castelar-Pinheiro GD; Brzezicki J; Hrycaj P; Graham NM; van Hoogstraten H; Bauer D; Burmester GR
Arthritis Rheumatol; 2017 Feb; 69(2):277-290. PubMed ID: 27860410
[TBL] [Abstract][Full Text] [Related]
13. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
Rubbert-Roth A; Enejosa J; Pangan AL; Haraoui B; Rischmueller M; Khan N; Zhang Y; Martin N; Xavier RM
N Engl J Med; 2020 Oct; 383(16):1511-1521. PubMed ID: 33053283
[TBL] [Abstract][Full Text] [Related]
14. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data.
Rehberg M; Giegerich C; Praestgaard A; van Hoogstraten H; Iglesias-Rodriguez M; Curtis JR; Gottenberg JE; Schwarting A; Castañeda S; Rubbert-Roth A; Choy EHS;
Rheumatol Ther; 2021 Dec; 8(4):1661-1675. PubMed ID: 34519964
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.
Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Zhou Y; Othman AA; Pangan AL; Kitamura S; Meerwein S; Tanaka Y
Rheumatology (Oxford); 2020 Nov; 59(11):3303-3313. PubMed ID: 32277824
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis.
Ma L; Xu C; Paccaly A; Kanamaluru V
Clin Pharmacokinet; 2020 Nov; 59(11):1451-1466. PubMed ID: 32451909
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
[TBL] [Abstract][Full Text] [Related]
19. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
Rubbert-Roth A; Furst DE; Fiore S; Praestgaard A; Bykerk V; Bingham CO; Charles-Schoeman C; Burmester G
Arthritis Res Ther; 2022 Aug; 24(1):207. PubMed ID: 36008838
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Fleischmann RM; Genovese MC; Enejosa JV; Mysler E; Bessette L; Peterfy C; Durez P; Ostor A; Li Y; Song IH
Ann Rheum Dis; 2019 Nov; 78(11):1454-1462. PubMed ID: 31362993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
